763D Concord Avenue
About UltivueUltivue develops innovative reagent-based solutions that maximize the biological information available from cells and tissue samples. The company’s patent-pending technology is being used to elucidate biological pathways and to validate clinically-relevant biomarkers. Ultivue is based in Cambridge, MA.
Co-Founder: Peng Yin
Co-Founder: David Walt
Co-Founder: Ralf Jungmann
CTO: Michael Natan
Please click here for Ultivue job opportunities.
Please click here for Ultivue's products.
15 articles with Ultivue
Ultivue announces the addition of new executive team members in order to help strengthen its position as a leading assay development solutions provider for multiplex biomarker analysis for tissue phenotyping . Mike Sismour, PhD has joined Ultivue in the role of Vice President, Research, and Mark Rees, PhD has joined as Vice President, Corporate Development.
Ultivue to Participate in Cowen’s 41 st Annual Health Care Conference
Ultivue and Indivumed today announced that the two companies have entered into a collaborative partnership to further accelerate research and drug development in the area of personalized oncology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005281/en/ The deal links Indivumed’s vast array of standardized and fully c
Ultivue, the innovation leader in tissue biomarker identification and quantification assays for translational and pathology research labs, today announced the close of a $22 Million Series C funding led by new investor Northpond Ventures and fueled by existing investors including ARCH Venture Partners, 6 Dimensions Capital, Yonghua Capital, and Applied Ventures.
Definiens and Ultivue Announce a Collaboration to Co-Develop Joint Offerings in Multiplexed Immunofluorescence (IF) and AI Enabled Digital Image Analysis
Ultivue, a developer of tissue biomarker identification and quantification assays for translational and pathology research labs, and Definiens, a pioneer in artificial intelligence (AI) based image analysis, today announced a collaboration to expand Definiens standardized IO-Panel capabilities to IF.
Ultivue releases breakthrough innovations for multiplex IHC: 16-marker whole-slide visualization and high marker co-localization in FFPE tissue
Ultivue unveiled the expanded capabilities of its proprietary InSituPlex® DNA-barcoding and staining technology through comprehensive visualization of a whole slide 16-marker multiplex assay in tissue.
Mr. Pirovano is an international executive with significant experience managing European Diagnostics and Life Science operations and will be responsible for managing the new subsidiary, Ultivue EMEA Srl, located in Milan, Italy.
Ultivue to Release a Breakthrough 9-Color Multiplex IHC Panel Achieving Same Day Sample-to-Analysis at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2018
Ultivue, a life science company developing reagent-driven strategies for high-performance biological imaging in situ, today announced expanded capabilities of its proprietary InSituPlex® DNA-barcoding and staining technology.
Ultivue Expands Its Portfolio of Digital Quantitative Pathology Services with a Suite of Image Analysis Capabilities Powered by Indica Labs HALO™, HALO LINK™ and Amazon Web Services
Ultivue has announced today the expansion of its menu of Digital Quantitative Pathology Services with a complete suite of Image Analysis capabilities.
NuProbe Global announced today the formation of its Scientific Advisory Board (SAB) with genomics pioneers George M. Church, Ph.D. and David R. Walt, Ph.D.
Ultivue Launches UltiMapper™ Portfolio of Reagents for Tissue Marker Detection and Analysis at High Level of Multiplexing and Throughput, with Seamless Use in Current Immuno-Histochemistry Workflows.
Ultivue has announced the public launch of its UltiMapper™ portfolio of reagents enabling the highest throughput of whole-slide, protein biomarker analysis and spatial detection in tissue, at high level of multiplexing, using instrumentation and software solutions currently found in most Immuno-Histochemistry laboratories.
Ultivue Inc. announced today that it has closed a $20 million Series B funding round led by existing investor ARCH Venture Partners.
Ultivue Launches InSituPlex Services for Whole Slide, High Definition Spatial Multiplex Tissue Biomarker Analysis
The service offering relies on the company’s proprietary InSituPlex technology that supports unbiased biomarker analysis in tissue at a high level of multiplex and with high spatial resolution.